Education
About Us
Working with TipRanks
Follow Us
Cyclopharm Limited (AU:CYC)
ASX:CYC
CYC Stock Chart & Stats
AU$0.98
-AU$0.04(-1.82%)
At close: 4:00 PM EST
AU$0.98
-AU$0.04(-1.82%)
Day’s Range― - ―
52-Week RangeAU$0.56 - AU$1.55
Previous CloseN/A
Volume20.15K
Average Volume (3M)97.64K
Market Cap
AU$88.05M
Enterprise ValueAU$96.34M
Total Cash (Recent Filing)AU$6.63M
Total Debt (Recent Filing)AU$14.92M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding120,610,535
10 Day Avg. Volume155,345
30 Day Avg. Volume97,642
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$47.80M
Bulls Say, Bears Say
Bulls Say
Revenue Growth / Commercial TractionConsistent top-line growth through 2025 indicates enduring commercial traction for Technegas and expanding procedure volumes. Steady revenue supports scale economics for consumables and signals growing clinical adoption that should continue to underpin recurring sales over the next several months.
Recurring Consumables Business ModelThe business model generates recurring revenue tied to each patient study, creating repeatable demand as the installed base grows. Consumables provide predictable, volume-linked revenues that are structurally durable versus one-off sales, anchoring long-term cash flows if procedure volumes remain stable or rise.
Equity Buffer Supports OperationsA solid equity base provides a cushion to fund continued operating losses and funding gaps in the near term. This balance-sheet strength increases resilience to short-term shocks and gives management time to execute on commercial growth or restructuring without immediate insolvency risk.
Bears Say
High Cash Burn / Negative Operating Cash FlowPersistent and large negative operating cash flow and free cash flow indicate structural cash burn that will require external financing or material margin improvement. Over 2-6 months this raises funding risk, potential dilution, and constraints on investments or commercial expansion unless cash generation reverses.
Margin Deterioration And Widening LossesA negative gross profit signals that production or direct costs exceeded revenue, undermining core unit economics. Worsening losses suggest structural margin problems—pricing, cost control, or mix—that threaten long-term sustainability unless addressed through pricing changes, cost reductions, or productivity gains.
Rising Leverage And Balance Sheet PressureMaterial debt increase alongside declining equity raises financial risk and reduces flexibility to fund operations. Higher leverage increases interest and covenant risks, limiting strategic options and heightening refinancing risk over the medium term if cash flow does not improve.
Cyclopharm Limited News
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$0.56 and its highest was AU$1.55 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$88.05M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Sep 01, 2026 which is in 177 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.087 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.087.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Overvalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 120,610,535 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.087 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cyclopharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CYC Sentiment 87%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.35%
12-Months-Change
Fundamentals
Return on Equity
-31.98%
Trailing 12-Months
Asset Growth
-12.76%
Trailing 12-Months
Company Description
Cyclopharm Limited
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―